| ID Source | ID |
|---|---|
| PubMed CID | 128768 |
| MeSH ID | M0138552 |
| Synonym |
|---|
| OPREA1_787798 |
| tegalid |
| STK378900 |
| 3,5-dibromo-n-{4-chloro-3-[(4-chlorophenyl)carbonyl]phenyl}-2-hydroxybenzamide |
| tegalide |
| 3,5-dibromo-n-[4-chloro-3-(4-chlorobenzoyl)phenyl]-2-hydroxybenzamide |
| 67358-44-5 |
| AKOS001584107 |
| benzamide, 3,5-dibromo-n-(4-chloro-3-(4-chlorobenzoyl)phenyl)-2-hydroxy- |
| sr-01000388989 |
| SR-01000388989-1 |
| 3,5-dibromo-n-(4-chloro-3-(4-chloro-benzoyl)-phenyl)-2-hydroxy-benzamide |
| 3,5-dibromo-n-[4-chloro-3-(4-chlorobenzoyl)phenyl]-2-hydroxybenzene-1-carboximidic acid |
| DTXSID00986618 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " As the fine-dispersed fraction of Tegalide increased, its bioavailability showed an equivalent increase." | ( [The effect of the dispersity of tegalid on its bioavailability]. Khalikov, SS; Lebedeva, MN; Lopatina, NB; Mikhaĭlitsyn, FS, ) | 0.41 |
| " The agent as tablets has a higher bioavailability than its substance." | ( [Comparative biopharmaceutical study of tegalide]. Lebedeva, MN; Lopatina, NB, ) | 0.4 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||